Biotechnology company Immunic Therapeutics has appointed Erik Lundgren as Chief Executive Officer. Immunic says Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development. Vidofludimus calcium has shown therapeutic activity in Phase II clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Lundgren recently served… Read More
What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics’ recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective… Read More
This is the latest episode of the free DDW podcast, “Streamlining gene therapy manufacturing and how MS provides information on virus structure”. It covers two narrated articles written for DDW and is read aloud by Megan Thomas, both of which were published in Volume 22, Issue 1 – Winter 2020/21… Read More
In this podcast, Megan Thomas narrated two articles in which Akash Bhattacharya, the Senior Application Scientist at Beckman Coulter Life Sciences, explains how streamlining gene therapy manufacturing will help products reach more patients, and Andreas Huhmer, Senior Director of Proteomics and Metabolomics at Thermo Fisher Scientific, discusses the value of… Read More
Octopus, a world-first mega-trial for progressive multiple sclerosis (MS), will launch in the UK later in 2021, according to the MS Society. It is a clinical trial that is said will transform the way treatments for progressive MS are tested and could deliver new options up to three times faster. Read More
Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models – created using stem cells from human skin samples – will be… Read More
Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially? More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly,… Read More
